Can neoadjuvant endocrine therapy de-escalate surgery in luminal breast cancer? A four-year retrospective study from a single referral center
Frontiers in Oncology · 28.07.2026 · 16
DOI: 10.3389/fonc.2026.1831764 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 28.07.2026. Verfasst von Aleksander Skulimowski und 6 weiteren Autor:innen. Beteiligte Einrichtung: Breast Unit, II Department of Surgical Oncology, Lower Silesian Center of Oncology, Pulmonology, and Hematology, Wroclaw, Poland. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Uniwersytet Medyczny im. Piastόw Slaskich we Wroclawiu.
Abstract (Originalsprache)
Introduction
Postmenopausal women commonly present with HR-positive/HER2-negative breast cancer. Neoadjuvant endocrine therapy (NET) may facilitate breast-conserving surgery (BCS) and de-escalation of axillary surgery. This study evaluated NET efficacy in enabling surgical de-escalation in luminal breast cancer. Materials and methods A retrospective study included postmenopausal women (≥49 years) with newly diagnosed, luminal breast cancer treated with NET between May 2021 and May 2024 at a single tertiary breast unit. Patients with stage IV disease or contraindications to surgery were excluded. Clinical and pathologic variables were collected from chart review. Tumor and nodal downstaging were defined by decrease of at least one level from clinical (cT or cN) to pathologic (ypT or ypN) stage. Multivariable logistic regression was used to identify predictors of downstaging.
Results
A total of 124 patients (128 tumors) were included. Mean age at diagnosis was 69 years. NET resulted in a significant reduction in tumor size (mean absolute reduction 10.93 mm; p < 0.0001; mean relative reduction 23.4%; p < 0.0001). BCS was achieved in 75.8% of cases, and NET was estimated to have avoided mastectomy in at least 27 patients. Lobular histology (OR 2.92, 95% CI 1.20–7.00; p = 0.017) and absence of clinical nodal involvement (OR 3.10, 95% CI 1.45–6.55; p = 0.003) were independently associated with T-stage downstaging. Regarding axillary management, 75.8% underwent sentinel lymph node biopsy and 22.7% upfront axillary lymph node dissection. Among patients initially managed with SLNB, 35% required completion ALND. Of 60 clinically node-positive (cN1) patients, 8 (12.7%) achieved ypN0 status after NET. Micrometastatic residual disease was observed in 4 additional cases (6.3% of cN1 patients).
Conclusions
NET effectively facilitates breast-conserving surgery in postmenopausal patients with luminal breast cancer. However, its impact on achieving nodal clearance and reducing axillary dissection remains limited.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Breast Unit, II Department of Surgical Oncology, Lower Silesian Center of Oncology, Pulmonology, and Hematology, Wroclaw, Poland.
- Department of Oncology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland.
- Department of Oncology, Lower Silesian Center of Oncology, Pulmonology, and Hematology, Wroclaw, Poland.
- Department of Endocrinology, Diabetology and Internal Medicine, Tadeusz Marciniak Lower Silesia Specialist Hospital-Centre for Medical Emergency, Wroclaw, Poland.
- Department of Radiology, Lower Silesian Center of Oncology, Pulmonology, and Hematology, Wroclaw, Poland.
Förderung
- Uniwersytet Medyczny im. Piastόw Slaskich we Wroclawiu
Zitieren
APA
Skulimowski, A., Skórniak, J., Michalik, T., Ekiert, M., Skulimowska, K., Kasprzak, P., & Matkowski, R. (2026). Can neoadjuvant endocrine therapy de-escalate surgery in luminal breast cancer? A four-year retrospective study from a single referral center. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1831764
Vancouver
Skulimowski A, Skórniak J, Michalik T, Ekiert M, Skulimowska K, Kasprzak P, et al. Can neoadjuvant endocrine therapy de-escalate surgery in luminal breast cancer? A four-year retrospective study from a single referral center. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1831764
BibTeX
@article{Skulimowski2026,
author = {Skulimowski, Aleksander and Skórniak, Jakub and Michalik, Tomasz and Ekiert, Marcin and Skulimowska, Karolina and Kasprzak, Piotr and Matkowski, Rafał},
title = {Can neoadjuvant endocrine therapy de-escalate surgery in luminal breast cancer? A four-year retrospective study from a single referral center},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1831764}
}
EUVIMED